Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis

NCT02816476 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University Hospital, Limoges